Cover Image
市場調查報告書

癲癇:流行病學·基於患者之市場預測,治療流程,上市藥·開發平台藥物分析

Epilepsy: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis

出版商 Datamonitor Healthcare 商品編碼 365216
出版日期 內容資訊 英文 326 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
癲癇:流行病學·基於患者之市場預測,治療流程,上市藥·開發平台藥物分析 Epilepsy: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis
出版日期: 2016年06月01日 內容資訊: 英文 326 Pages
簡介

本報告提供癲癇治療藥市場相關調查分析,市場預測,治療,流行病學,上市藥,開發平台藥物趨勢等系統性資訊。

預測:癲癇

  • 摘要整理
  • 市場概要·趨勢
  • 市場定義·手法
  • Aptiom/Zebinix (eslicarbazepine)
  • Fycompa (perampanel)
  • Lyrica (pregabalin)
  • Potiga/Trobalt (ezogabine/retigabine)
  • Rikelta (brivaracetam)
  • Vimpat (lacosamide)
  • 1次調查手法

治療:癲癇

  • 摘要整理
  • 1次調查手法
  • 疾病定義·診斷
  • 患者區分
  • 目前治療選擇
  • 治療趨勢
  • 未滿足需求

流行病學:癲癇

  • 摘要整理
  • 疾病的背景
  • 資訊來源·手法
  • 預測
  • 流行病學者的考察
  • 優點·缺點
  • 附錄

上市藥:癲癇

  • 摘要整理
  • 產品概要
  • 其他上市藥
  • 產品簡介:Aptiom
  • 產品簡介:Banzel
  • 產品簡介:Briviact
  • 產品簡介:Fycompa
  • 產品簡介:Keppra,Keppra XR
  • 產品簡介:Lamictal,Lamictal XR
  • 產品簡介:Lyrica
  • 產品簡介:Onfi
  • 產品簡介:Potiga
  • 產品簡介:Vimpat

開發平台:癲癇

  • 摘要整理
  • 臨床實驗平台概要
  • 產品簡介 (後期) :Epidiolex
  • 產品簡介 (後期) :ganaxolone

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC4760

Refractory patients, niche indication expansions, and geographical reach offer room for growth in an otherwise crowded epilepsy market.

This report addresses the following questions:

  • Why do leading antiepileptic drugs retain a large amount of brand loyalty, despite loss of exclusivity and cheap direct competition?
  • Who are the future market leaders in the treatment of epilepsy?
  • Which patient subgroups will have the largest impact on epilepsy sales?
  • What are the drug companies' strategies when penetrating a highly crowded market to achieve profitability?
  • What are epilepsy's unmet needs that could be addressed by drug companies?

TABLE OF CONTENTS

FORECAST: EPILEPSY

  • 1. Executive Summary
  • 2. Market Overview and Trends
  • 3. Market Definition and Methodology
  • 4. Aptiom/Zebinix (eslicarbazepine)
  • 5. Fycompa (perampanel)
  • 6. Lyrica (pregabalin)
  • 7. Potiga/Trobalt (ezogabine/retigabine)
  • 8. Rikelta (brivaracetam)
  • 9. Vimpat (lacosamide)
  • 10. Primary Research Methodology

TREATMENT: EPILEPSY

  • 11. Executive Summary
  • 12. Primary Research Methodology
  • 13. Disease Definition and Diagnosis
  • 14. Patient Segmentation
  • 15. Current Treatment Options
  • 16. Treatment Dynamics
  • 17. Unmet Needs in Epilepsy

EPIDEMIOLOGY: EPILEPSY

  • 18. Executive Summary
  • 19. Disease Background
  • 20. Sources and Methodology
  • 21. Forecast
  • 22. Epidemiologist Insight
  • 23. Strengths and Limitations
  • 24. Appendix

MARKETED DRUGS: EPILEPSY

  • 25. Executive Summary
  • 26. Product Overview
  • 27. Other Marketed Drugs
  • 28. Product profile: Aptiom
  • 29. Product profile: Banzel
  • 30. Product profile: Briviact
  • 31. Product profile: Fycompa
  • 32. Product profile: Keppra and Keppra XR
  • 33. Product profile: Lamictal and Lamictal XR
  • 34. Product profile: Lyrica
  • 35. Product profile: Onfi
  • 36. Product profile: Potiga
  • 37. Product profile: Vimpat

PIPELINE: EPILEPSY

  • 38. Executive Summary
  • 39. Clinical Pipeline Overview
  • 40. Product profile (late stage): Epidiolex
  • 41. Product profile (late stage): ganaxolone
Back to Top